683 Capital Management’s Sage Therapeutics SAGE Stock Holding History

683 Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,150,000	Closed	-$10.5M	–	155
2025 Q2	$10.5M	Buy	1,150,000 +150,000	+15%	+$1.1M	0.69%	40
2025 Q1	$7.95M	Buy	1,000,000 +370,000	+59%	+$2.71M	0.55%	53
2024 Q4	$3.42M	Buy	630,000 +30,000	+5%	+$183K	0.21%	76
2024 Q3	$4.33M	Buy	600,000 +100,000	+20%	+$916K	0.33%	65
2024 Q2	$5.43M	Buy	500,000 +300,000	+150%	+$3.84M	0.41%	57
2024 Q1	$3.75M	Buy	+200,000	New	+$4.61M	0.27%	66

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

683 Capital Management's SAGE Position: Q3 2025 in Review

683 Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,150,000 shares — an estimated $10.5M sold.

683 Capital Management first reported a position in SAGE in Q1 2024 and held it in 6 quarters. The position peaked at $10.5M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

683 Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
683 Capital Management sold 1,150,000 Sage Therapeutics shares in Q3 2025, an estimated $10.5M.
683 Capital Management first reported a position in Sage Therapeutics in Q1 2024 and held it in 6 quarters.
683 Capital Management's Sage Therapeutics position peaked at $10.5M in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on 683 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.